Long-acting PEG-rhG-CSF Market

Future Market Insights

Key Insight

The long-acting PEG-rhG-CSF market is projected to grow from USD 3.4 billion in 2025 to USD 6.6 billion by 2035, at a CAGR of 6.8%. Innovative Drugs will dominate with a 52.0% market share, while neoplastic diseases will lead the application segment with a 73.0% share.

November 07, 2025

Anurag Sharma

250 Pages

Cite this Report

Long-acting PEG-rhG-CSF Market

https://www.futuremarketinsights.com/reports/long-acting-peg-rhg-csf-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Amgen
Biocon Biologics Inc
CSPC
Coherus BioSciences
Fresenius Kabi AG
Jiangsu Hengrui Medicine
Mylan
The Vanguard Group
Qilu Pharmaceutical
Sandoz (Novartis AG)

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Long-acting PEG-rhG-CSF Market

Key Players

Similar Industry Reports